Search
for
Sort by
Research 30 of 1000+
- Permanent Localized Hair Repigmentation Following Herpes Zoster Infection
- Low concentration zinc sulphate solution in the management of recurrent herpes simplex infection
- Down-RANKing the Threat of HSV-1: RANKL Upregulates MHC-Class-I-Restricted Anti-Viral Immunity in Herpes Simplex Virus Infection
- 1389 Local injection with anti-herpes simplex virus antibodies protects against development of herpes simplex virus–induced sweating disturbance
- 019 Herpes simplex virus infection in pemphigus patients: a prospective study
- Herpes Zoster Development After Intraarticular Sodium Hyaluronate Injection
- Mucocutaneous manifestations in children with human immunodeficiency virus infection
- [Mycophenolate mofetil in induction and maintenance therapy for juvenile onset severe lupus nephritis].
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Hair and Scalp Infections
- Cutaneous manifestations of HIV infection other than Kaposi's sarcoma: Clinical and histologic aspects
- Cutaneous manifestations associated with COVID-19 infection at a university hospital in eastern China
- Operational research on the correlation between skin diseases and HIV infection in Tigray region, Ethiopia
- Kaposi varicelliform eruption
- British Hair and Nail Society
- DENOUEMENT—CONTINUED FROM P. 661
- Dermatoses of pregnancy
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- A clinical study of Geriatric dermatoses at Tertiary care center in South India
- A CLINICAL STUDY OF MUCOCUTANEOUS MANIFESTATIONS OF HIV
- Seasonal Patterns and Trends in Dermatoses in Poland
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- The skin findings of pregnant women and our treatment choices. A Turkish experience: a 5-year survey.
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Cutaneous Side Effects of Oral Contraceptives
- Dermatological Issues Among Individuals Receiving Palliative Care - A Review
- Keloids After Herpes Zoster: Report of Wolf’s Isotopic Phenomenon and Literature Review